Publications by authors named "Louise Photiou"
Solar urticaria (SU) is a rare form of urticaria with a pathogenesis that is poorly understood. It affects all skin types, can be difficult to diagnose, and is challenging to manage effectively. We conducted a retrospective review of patients with SU in our institution.
View Article and Find Full Text PDFAlopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia universalis.
View Article and Find Full Text PDFArticle Synopsis
- - Frontal fibrosing alopecia (FFA) is a type of hair loss that permanently damages hair follicles, and its causes are not completely understood, involving factors like immune response, genetics, hormones, and environment
- - The condition appears to be on the rise globally, particularly among post-menopausal women, and may share similarities with other forms of hair loss, suggesting hormonal influences and possible genetic links
- - There is a need for more research to understand FFA's complex causes and to develop better treatment options, especially given its increasing incidence and impact on those affected
Purpose Of Review: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease.
View Article and Find Full Text PDFBackground/objectives: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilizes data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change.
Methods: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted.